AbbVie unwrapped a Phase 3 success on Thursday for an experimental drug designed to treat a debilitating skin disease.
In the trial, AbbVie’s IL-1α and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.